Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • AI and healthcare
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
      • Top Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • AI and healthcare
    • Industry Perspective
  • Home
  • Medicine
  • Medicine News
  • CagriSema Shows...

CagriSema Shows Significant Weight Loss and Improved Physical Function in REDEFINE 1 Trial

Written By : Dr. Kamal Kant Kohli Published On 2026-11-16T21:15:45+05:30  |  Updated On 16 Nov 2026 9:15 PM IST
CagriSema Shows Significant Weight Loss and Improved Physical Function in REDEFINE 1 Trial
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email
A post hoc analysis of the Phase 3 REDEFINE 1 trial demonstrated promising weight-loss and functional benefits with investigational CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) in adults with overweight or obesity.
Early weight-loss response: 67.8% of participants achieved at least 5% weight loss by week 81. Women were more likely than men to be early responders (71.8% vs 59.5%).
Improved physical function: At week 68, significantly more participants receiving CagriSema reported meaningful improvements in physical function compared with placebo (73.1% vs 49.1%).
Clinical Significance: CagriSema may offer dual benefits in obesity management, promoting substantial weight loss while improving physical functioning and quality of life. These findings are from post hoc analyses and require confirmation in further studies.

"Obesity is a chronic disease, and people respond to treatment differently and over different timeframes," said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. "That is why we continue to study the REDEFINE 1 data in greater depth. In this post hoc analysis, most people treated with CagriSema 2.4 mg / 2.4 mg were early responders, meaning they lost at least 5% of their body weight within the first 8 weeks of treatment. Together with the patient-reported physical function results, this research adds to the growing evidence base from the REDEFINE clinical program."

Early response and weight loss trajectories (post hoc analysis)

In this post hoc analysis, 67.8% of CagriSema-treated participants were early responders (at least 5% weight loss at week 8). Observed mean weight loss at week 68 was 25.4% among early responders. Among delayed responders, observed mean weight loss at week 68 was 17.8%.‡ Women were more likely to be early responders than delayed responders (71.8% vs 59.5%).

Weight loss by early response status with CagriSema 2.4 mg / 2.4 mg in REDEFINE 1 (post hoc analysis; observed data).

Outcome Early responders (n=1,367) Delayed responders (n=649)
Mean weight loss at week 8 7.80% 3.40%
Mean weight loss at week 68 25.40% 17.80%
Achieved ≥20% weight loss at week 68 73.30% 37.20%
Achieved ≥15% to <20% weight loss at week 68 16.10% 23.80%
Achieved ≥10% to <15% weight loss at week 68 7.90% 21.30%
Achieved ≥5% to <10% weight loss at week 68 2.50% 14.00%
Achieved <5% weight loss at week 68 0.30% 3.60%

Early responders: ≥5% weight loss at week 8; delayed responders: <5% weight loss at week 8. Weight loss categories at week 68 are mutually exclusive.

Observed data from the on-treatment period; post hoc analysis, hypothesis-generating.

"In clinical practice, it can be hard to know early on how an individual patient will respond to treatment," said Dr. W. Timothy Garvey, Department of Nutrition Sciences, University of Alabama at Birmingham, and author of the REDEFINE 1 early response analysis. "This post hoc analysis shows that people treated with CagriSema 2.4 mg / 2.4 mg experienced different weight loss trajectories, including onset of response to treatment. These values are hypothesis-generating, and they are not the basis for changing clinical decision-making."

Patient-reported physical and psychosocial function

The Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT), used in the REDEFINE 1 analysis, is a validated questionnaire used to assess how weight affects physical function, such as the ability to carry out everyday physical activities, and psychosocial function, such as self-esteem and comfort in social situations, including whether changes are meaningful to the individual.2

At week 68, 73.1% of adults treated with CagriSema 2.4 mg / 2.4 mg reported a meaningful within-person change in physical function vs 49.1% with placebo (post hoc analysis; efficacy estimand,* which assumes all participants adhered to treatment).2 In these post hoc analyses, 69.0% vs 42.1% reported a meaningful within-person change in psychosocial function, and the proportion reporting meaningful within-person change in physical function was significantly greater with CagriSema than with placebo from week 8 through week 68.2

Proportion of adults achieving a meaningful within-person change in IWQOL-Lite-CT scores at week 68 in REDEFINE 1 (post hoc analyses; efficacy estimand*)2

"In clinical practice, it can be hard to know early on how an individual patient will respond to treatment," said Dr. W. Timothy Garvey, Department of Nutrition Sciences, University of Alabama at Birmingham, and author of the REDEFINE 1 early response analysis. "This post hoc analysis shows that people treated with CagriSema 2.4 mg / 2.4 mg experienced different weight loss trajectories, including onset of response to treatment. These values are hypothesis-generating, and they are not the basis for changing clinical decision-making."

Patient-reported physical and psychosocial function

The Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT), used in the REDEFINE 1 analysis, is a validated questionnaire used to assess how weight affects physical function, such as the ability to carry out everyday physical activities, and psychosocial function, such as self-esteem and comfort in social situations, including whether changes are meaningful to the individual.

At week 68, 73.1% of adults treated with CagriSema 2.4 mg / 2.4 mg reported a meaningful within-person change in physical function vs 49.1% with placebo (post hoc analysis; efficacy estimand,* which assumes all participants adhered to treatment).2 In these post hoc analyses, 69.0% vs 42.1% reported a meaningful within-person change in psychosocial function, and the proportion reporting meaningful within-person change in physical function was significantly greater with CagriSema than with placebo from week 8 through week 68.

Proportion of adults achieving a meaningful within-person change in IWQOL-Lite-CT scores at week 68 in REDEFINE 1 (post hoc analyses; efficacy estimand*)

Outcome at week 68 CagriSema 2.4 mg / 2.4 mg (n=2,108) Placebo (n=705) Estimated treatment difference (95% CI)
Physical Function score 73.1 % 49.1 % 24.1% (19.5, 28.7)
Physical score 73.4 % 50.1 % 23.3% (18.7, 27.9)
Psychosocial score 69.0 % 42.1 % 26.9% (22.5, 31.4)
Total score 69.1 % 40.4 % 28.7% (24.2, 33.2)

*Efficacy estimand: treatment effect if all participants adhered to treatment.

Meaningful within-person change thresholds: 14.6 points (Physical Function), 13.5 points (Physical), 16.2 points (Psychosocial) and 16.6 points (Total).2

"Obesity goes far beyond the scale; my patients are more concerned with how weight affects their ability to move comfortably and participate confidently in everyday life," said Dr. Domenica Rubino, Washington Center for Weight Management and Research, co-author of the REDEFINE 1 physical and psychosocial function analysis. "In this post hoc analysis of REDEFINE 1, 73.1% of people treated with CagriSema 2.4 mg / 2.4 mg reported a meaningful improvement in physical function at week 68, compared with 49.1% of those receiving placebo. Additional post hoc analyses suggest these improvements may begin early in treatment, which warrants further study."

In the REDEFINE 1 trial, discontinuation due to adverse events occurred in 5.9% of participants receiving CagriSema versus 3.5% with placebo.3 Adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs 39.9% with placebo) including nausea (55% vs 12.6%), constipation (30.7% vs 11.6%), vomiting (26.1% vs 4.1%) and were mostly transient and mild-to-moderate in severity.

Novo filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema 2.4 mg / 2.4 mg for weight management. A decision is expected in Q4 2026. CagriSema is not approved for use in the United States. Safety and efficacy are not established. There is no guarantee that this investigational medicine will become commercially available for the uses under clinical investigation.

CagriSemaweight losscagrilintidesemaglutide

Medical Survey

Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Print Article
Show Full Article
Next Story
Recommended For You
NO DATA FOUND

Editorial

Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev Joshi

Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev...

Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination - Dr. Makarand Damle

Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination...

Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

Beyond the Lipid Panel: Elevated Lp(a), Lifetime Risk and What the Evidence Says About Aspirin- Dr Ambar Bhatnagar

Beyond the Lipid Panel: Elevated Lp(a), Lifetime Risk and What the Evidence Says About Aspirin- Dr...

View All

Journal Club Today

Replacing Dairy With Plant-Based Alternatives May Affect Iodine Intake, New Research Finds

Replacing Dairy With Plant-Based Alternatives May Affect Iodine Intake, New Research Finds

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok